Diagnosis and molecular classification of lung cancer

J Rodriguez-Canales, E Parra-Cuentas… - Lung Cancer: Treatment …, 2016 - Springer
Lung cancer is a complex disease composed of diverse histological and molecular types
with clinical relevance. The advent of large-scale molecular profiling has been helpful to …

Clinical implications of genomic discoveries in lung cancer

C Swanton, R Govindan - New England Journal of Medicine, 2016 - Mass Medical Soc
Clinical Implications of Genomic Discoveries in Lung Cancer | New England Journal of Medicine
Skip to main content The New England Journal of Medicine homepage Advanced Search …

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas

JD Campbell, A Alexandrov, J Kim, J Wala, AH Berger… - Nature …, 2016 - nature.com
To compare lung adenocarcinoma (ADC) and lung squamous cell carcinoma (SqCC) and to
identify new drivers of lung carcinogenesis, we examined the exome sequences and copy …

FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy

D Kazandjian, DL Suzman, G Blumenthal… - The …, 2016 - academic.oup.com
Abstract On October 9, 2015, the US Food and Drug Administration expanded the nivolumab
metastatic non-small cell lung cancer (NSCLC) indication to include patients with …

[HTML][HTML] Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

K Azuma, K Ota, A Kawahara, S Hattori, E Iwama… - Annals of oncology, 2014 - Elsevier
Background Recent clinical trials have shown that immune-checkpoint blockade yields a
clinical response in a subset of individuals with advanced nonsmall-cell lung cancer …

FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the …

CC Sun, W Zhu, SJ Li, W Hu, J Zhang, Y Zhuo… - Genome medicine, 2020 - Springer
Abstract Background Long non-coding RNAs (lncRNAs) are extensively intricate in the
tumorigenesis and metastasis of various cancer types. Nevertheless, the detailed molecular …

Induction of PD-L1 expression by the EML4–ALK oncoprotein and downstream signaling pathways in non–small cell lung cancer

K Ota, K Azuma, A Kawahara, S Hattori, E Iwama… - Clinical cancer …, 2015 - AACR
Purpose: Therapies targeted to the immune checkpoint mediated by PD-1 and PD-L1 show
antitumor activity in a subset of patients with non–small cell lung cancer (NSCLC). We have …

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised …

MC Garassino, O Martelli, M Broggini, G Farina… - The lancet …, 2013 - thelancet.com
Background Erlotinib is registered for treatment of all patients with advanced non-small-cell
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …

Refining the treatment of NSCLC according to histological and molecular subtypes

A Thomas, SV Liu, DS Subramaniam… - Nature reviews Clinical …, 2015 - nature.com
In the past decade, the characterization of non-small-cell lung cancer (NSCLC) into
subtypes based on genotype and histology has resulted in dramatic improvements in …

[HTML][HTML] Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

T Kohno, T Nakaoku, K Tsuta… - … lung cancer research, 2015 - ncbi.nlm.nih.gov
Fusions of the RET and ROS1 protein tyrosine kinase oncogenes with several partner genes
were recently identified as new targetable genetic aberrations in cases of non-small cell …